Clinical Trials Browser

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Carcinoma, Hepatocellular, Liver Neoplasms, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute

NCT06158828 2026-02-13

ABCD-NK

Phase 1/2 Recruiting

68 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07288073 2026-02-13

TIL Therapy in cSCC and MCC

Phase 2 Recruiting

14 enrolled

Dermatologic

Skin Neoplasms, Carcinoma, Merkel Cell

NCT06598371 2026-02-11

A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors

Phase 1/2 Recruiting

141 enrolled

Other solid neoplasm

Select Advanced Solid Tumors

NCT02964078 2026-02-10

Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer

Phase 2 Completed

27 enrolled 10 charts

Genitourinary

Kidney Diseases, Kidney Neoplasms, Neoplasm Metastasis

NCT03474497 2026-01-29

UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

Phase 1/2 Active not recruiting

18 enrolled 13 charts

DermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT04562129 2026-01-29

IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

Phase 2 Recruiting

29 enrolled

Dermatologic

Melanoma, Skin Neoplasms

NCT06236425 2026-01-08

TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC

Phase 1 Active not recruiting

7 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT05628883 2026-01-07

Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma

Phase 1 Active not recruiting

17 enrolled

Dermatologic

Uveal Melanoma, Melanoma

NCT06138587 2026-01-02

Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation

Phase 1 Recruiting

15 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Leukemia, Myeloid, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT01005745 2025-12-19

Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma

Phase NA Completed

19 enrolled 7 charts

Dermatologic

Melanoma

NCT01701674 2025-12-19

Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts

Phase NA Completed

13 enrolled 10 charts

Dermatologic

Melanoma, Skin Neoplasms

NCT05681780 2025-12-04

Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC

Phase 1 Active not recruiting

13 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06961357 2025-12-03

Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma

Phase 1/2 Recruiting

36 enrolled

Dermatologic

Uveal Melanoma, Melanoma

NCT01697527 2025-11-24

Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies

Phase 2 Active not recruiting

6 enrolled

Tumor-Agnostic

Neoplasms

NCT01857934 2025-11-17

Therapy for Children With Advanced Stage Neuroblastoma

Phase 2 Active not recruiting

153 enrolled 12 charts

CNS

Neuroblastoma

NCT05400122 2025-11-12

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

Phase 1 Suspended

12 enrolled

GastrointestinalLymphoidMyeloidOther hematologic neoplasmPlasma cell

Esophageal Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasm Metastasis, Rectal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07225439 2025-11-06

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Phase 1 Not yet recruiting

15 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05296564 2025-10-02

Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers

Phase 1/2 Recruiting

3 enrolled

BreastCNSDermatologicGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Sarcoma, Synovial, Triple Negative Breast Neoplasms

NCT05385705 2025-09-22

A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020

Phase 1 Terminated

2 enrolled

Breast

Breast Neoplasms

NCT06884670 2025-09-08

Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study

Phase 2 Recruiting

130 enrolled

Gastrointestinal

Rectal Neoplasms

NCT05080790 2025-08-17

DiTuSarc

Phase 2 Completed

7 enrolled

Sarcoma

Leiomyosarcoma

NCT06047977 2025-07-16

Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors

Phase 1 Recruiting

30 enrolled

Lymphocytes

NCT03991741 2025-07-03

Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors

Phase 1 Terminated

3 enrolled 9 charts

DermatologicHead & Neck

Head and Neck Neoplasms, Melanoma, Neoplasm Metastasis

NCT00994643 2025-04-30

Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma

Phase 2 Completed

11 enrolled 9 charts

Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin

NCT03610490 2025-04-17

Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma

Phase 2 Terminated

16 enrolled 11 charts

GastrointestinalGynecologic

Ovarian Neoplasms, Colorectal Neoplasms

Clinical Trials

CIML NK Cells With Venetoclax for AML

NK4AML

Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer

RIOT 4B

Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma

Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma

Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma

A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.

A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors

SELECT-CAR-NK

ABCD-NK

TIL Therapy in cSCC and MCC

A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors

Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer

UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC

Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma

Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation

Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma

Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts

Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC

Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma

Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies

Therapy for Children With Advanced Stage Neuroblastoma

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers

A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020

Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study

DiTuSarc

Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors

Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors

Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma

Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma